Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation
Language English Country Slovakia Media print
Document type Clinical Trial, Journal Article
PubMed
1382234
Knihovny.cz E-resources
- MeSH
- Bleomycin administration & dosage adverse effects MeSH
- Cyclophosphamide administration & dosage adverse effects MeSH
- Lymphoma, Large B-Cell, Diffuse drug therapy MeSH
- Adult MeSH
- Doxorubicin administration & dosage adverse effects MeSH
- Lymphoma, Large-Cell, Immunoblastic drug therapy MeSH
- Leucovorin administration & dosage adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Methotrexate administration & dosage adverse effects MeSH
- Prednisone administration & dosage adverse effects MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Vincristine administration & dosage adverse effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Names of Substances
- Bleomycin MeSH
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Leucovorin MeSH
- Methotrexate MeSH
- Prednisone MeSH
- Vincristine MeSH
Fifty patients with advanced (Stage III and IV) large cell and immunoblastic lymphoma were treated with eight 4-week courses of chemotherapy. The first two identical A courses were composed of high dose cyclophosphamide, vincristine, 5-day administration of bleomycin, 2-week prednisone, and methotrexate with calcium leucovorin. The next two "B" courses were composed of vincristine, 3-day administration of doxorubicin together with bleomycin, and prednisone. The next two "C" courses were composed of cyclophosphamide, vincristine, bleomycin, prednisone, methotrexate, and calcium leucovorin. The last two "D" courses were the same as "B" courses. CNS prophylaxis was done with intrathecal methotrexate. Fourty-two patients (84%) achieved complete remission, 7 patients entered partial remission, and 1 patient failed to respond. The median survival of all groups was 80 + months (range 2-181 + months). Nine patients relapsed (21%), and seven patients died in complete remission, three of them died of toxicity. The most frequent toxicity was myelosuppression, mostly leukopenia, frequently followed by infection, sometimes severe. Neurotoxicity and stomatitis were frequent, but usually not severe. Two patients developed secondary malignancies. Most of the patients (54%) are alive without evidence of disease at present.